Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications

Over the past ten years, sorafenib, a multikinase inhibitor, has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Whereas only recently lenvatinib was shown to be noninferior to sorafenib, in terms of survival, all other age...

Descripción completa

Detalles Bibliográficos
Autores principales: Personeni, Nicola, Pressiani, Tiziana, Santoro, Armando, Rimassa, Lorenza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038776/
https://www.ncbi.nlm.nih.gov/pubmed/30002715
http://dx.doi.org/10.7573/dic.212533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038776/
https://www.ncbi.nlm.nih.gov/pubmed/30002715
http://dx.doi.org/10.7573/dic.212533

Ejemplares similares